Cancers, Free Full-Text

Imatinib became the standard treatment for chronic myeloid leukemia (CML) about 20 years ago, which was a major breakthrough in stabilizing the pathology and improving the quality of life of patients. However, the emergence of resistance to imatinib and other tyrosine kinase inhibitors leads researchers to characterize new therapeutic targets. Several studies have highlighted the role of histone deacetylase 6 (HDAC6) in various pathologies, including cancer. This protein effectively intervenes in cellular activities by its primarily cytoplasmic localization. In this review, we will discuss the molecular characteristics of the HDAC6 protein, as well as its overexpression in CML leukemic stem cells, which make it a promising therapeutic target for the treatment of CML.

Cancer - Wiley Online Library

Kidney Cancer: Symptoms, Signs, Causes & Treatment

Multimodal analysis of methylomics and fragmentomics in plasma cell-free DNA for multi-cancer early detection and localization

What is cancer of unknown primary (CUP)?

Emerging Utility of Urinary Cell-free Nucleic Acid Biomarkers for Prostate, Bladder, and Renal Cancers - European Urology Focus

Free PSD Breast cancer awareness editable text effect

Pathology Outlines - Carcinoma-general

MD Anderson Cancer Center: Cancer Treatment & Cancer Research Hospital

Circulating Tumor Cells, Disease Progression, and Survival in Metastatic Breast Cancer

8 Ways to prevent cancer & be healthy -Siteman Cancer Center

IASLC International Association for the Study of Lung Cancer

Kidney Cancer Text · Free Stock Photo